

# Program

---





## Wednesday, 6 November 2019

8:00 AM Welcome  
**Harry Janssen**

### Session 1 Review of Nucleoside Analogue Stopping Studies *Chairs: Marion Peters & David Wong*

8:10 AM **Stopping Nucleos(t)ide Analogues: Clinical Outcomes of HBs Loss, Retreatment and Flares**  
**Pietro Lampertico, MD, PhD**  
Fondazione Policlinico - University of Milan, Italy

8:25 AM **Virological Biomarkers in Patients Stopping Nucs**  
**Florian van Bömmel, PD Dr. med.**  
Leipzig University, Germany

8:40 AM **Immunological Response after Stopping Nucs**  
**André Boonstra, PhD**  
Erasmus Medical Center, The Netherlands

8:55 AM **Discussion**

### Session 2 New Endpoints and Biomarkers *Chairs: Robert Gish & Scott Fung*

9:20 AM **Review of the EASL-AASLD HBV Endpoints Workshop**  
**Fabien Zoulim, MD, PhD**  
INSERM, France

9:35 AM **Are HBcrAg, HBV RNA and anti-HBc Viable Biomarkers**  
**Florian van Bömmel, PD Dr. med.**  
Leipzig University, Germany

9:50 AM **Are ALT Flares Associated with Improved Virological Clearance**  
**Harry Janssen, MD, PhD**  
Toronto Center for Liver Disease, Canada

10:05 AM **Discussion**

10:25 AM Coffee break



## Session 3 How to make Immunology Curative

*Chairs: Adam Gehring & Georg Lauer*

- 10:40 AM **High Resolution Analysis of Exhausted T Cells Ex Vivo in Chronic HBV Infection**  
**Robert Thimme, MD**  
University of Freiburg, Germany
- 10:55 AM **Restoration of B cell Antibody Production in Chronic HBV Patients**  
**Mala Maini, MD, PhD**  
University College London, United Kingdom
- 11:10 AM **Using FNAB to Investigate Intrahepatic Immunology**  
**Adam Gehring, PhD**  
Toronto Center for Liver Disease, Canada
- 11:25 AM **Spring Bank RIG-I Agonist**  
**Chelsea MacFarlane, PhD**  
Spring Bank Pharmaceuticals, United States
- 11:35 AM **Gilead TLR8 Agonist**  
**Simon Fletcher, PhD**  
Gilead Sciences, United States
- 11:45 AM **Roche TLR-7 Agonist**  
**Lu Gao, PhD**  
Roche R&D Center (China), China
- 11:55 AM **Discussion**

12:30 PM Lunch

## Session 4 Update on Viral Targets for HBV/HDV Therapy

*Chairs: Stephen Locarnini & Raymond Schinazi*

- 1:30 PM **Mechanisms of cccDNA Maintenance and Progress on Measurement**  
**Massimo Levrero, MD**  
Cancer Research Center of Lyon, France
- 1:45 AM **cccDNA Inhibitor - Roche**  
**Lu Gao, PhD**  
Roche R&D Center (China), China
- 1:55 PM **Assembly CpAM**  
**Richard Colonno, PhD**  
Assembly Biosciences, United States
- 2:05 PM **sIRNA Based Therapy for Chronic Hepatitis B Treatment**  
**Michael Biermer, PhD**  
Johnson & Johnson - Janssen, Germany



2:15 PM **NAP's Latest Update in HBV and HDV**  
**Andrew Vaillant, PhD**

Replicor Inc., Canada

2:25 PM **MyrB + IFN Effect on HBV & HDV**  
**Stephan Urban, PhD**

University Hospital of Heidelberg, Germany

2:35 PM **Lonafarnib and Peginterferon Lambda: First-in-class Drugs for HDV Infection in Late Stage Clinical Development**  
**Robert Gish, MD**

Robert G Gish Consultants LLC, United States

2:45 PM **Discussion**

3:30 PM Coffee break

## Session 5 **New Drug Combinations and Study Design**

*Chairs: Harry Janssen & Fabien Zoulim*

3:45 PM **FDA Guidance on New Combinations**  
**Poonam Mishra, MD, MPH, FAASLD**

Us Food And Drug Administration, United States

4:00 PM **Hypothesized Synergies in New Combination Treatment Beyond Nucs**  
**Jordan Feld, MD, MPH**

Toronto Center for Liver Disease, Canada

4:15 PM **Study Design with New Combinations**  
**Marion Peters, MD**

University of California, United States

4:30 PM **Discussion**

5:15 PM **Closing Remarks**  
**Harry Janssen**

